Startup Spotlight: EnsoData’s AI diagnosis solution
Wisconsin-based EnsoData is a startup utilising artificial intelligence for the diagnosis of health conditions.
The company’s technology transforms waveform data points, commonly used in healthcare, into human-readable reports for clinicians, identifying patterns and events to aid in clinical diagnosis.
Waveform data is ubiquitous in healthcare situations, generated by such things as heartbeats through an EKG or brain waves through an EEG. The company said that over 1.5 billion waveforms were run per year, a volume EnsoData is focused on making more digestible.
Since its foundation in 2015, the company has raised over $11mn. Its latest Series A round, announced on 10 June, netted the company $9mn from lead investors Zetta Venture Partners and Venture Investors. Also participating were SleepScore ventures, Necessary Ventures and Dreamit Ventures.
The company said it would use the funding to, among other aims, grow its team and launch new AI products for sleep and neurology. Sleep is the company’s initial focus, with its flagship EnsoSleep product intended for use by sleep technicians to diagnose conditions such as sleep apnea.
"Sleep apnea is a condition that plagues nearly one billion people worldwide, and we're uniquely positioned to address this massive problem," said Chris Fernandez, CEO of EnsoData in a press release. "We know that not everyone has access to quality and affordable treatment, and have the conviction that our technology can help bridge that gap. Automating waveform data analysis saves clinicians significant time, and labs and healthcare systems significant money, so they can focus on what really matters -- the patients and what's literally keeping them up at night."
"We believe that EnsoData will be a game-changer for the way we diagnose and treat patients," said Mark Gorenberg, Managing Director at Zetta Venture Partners. "Sleep is just the beginning. Waveform AI may be the lowest cost, most scalable, and most widely available tool for diagnosing patients. It will seriously advance our understanding of health and the human body."